IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (IRWD)

CUSIP: 46333X108

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Class A Common Stock
Total 13F shares
146,448,573
Total 13F value
$105,056,220
Holder snapshot 6 visible 7 signals
Share change
-8,784,469
Put/Call ratio
0%
SEC-reported price per share
$0.72
Number of holders
151
Value change
-$19,990,203
Number of buys
77
Open additional details 1 more signal available
Number of sells
116
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
163,317,295

Security key

46333X108

Report period

Q2 2025

Institutions

151

Top holders

10

IRWD full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 IRONWOOD PHARMACEUTICALS INC SEC filings IRONWOOD PHARMACEUTICALS INC company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of IRWD - IRONWOOD PHARMACEUTICALS INC - Class A Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Sarissa Capital Managemen...
Comparable rows
15/15
Latest evidence
10 Jun 2025
13F 13D/G 3/4/5 Lead comparable stake: 10% 13D/G row: VANGUARD GROUP INC Showing 1-6 of 15 holder rows.

Quick read

VANGUARD GROUP INC leads the comparable SEC ownership view at 10%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership Top 5
VANGUARD GROUP INC 10%
BlackRock, Inc. 7.1%
RENAISSANCE TECHNOLOGIES LLC 5.4%
STATE STREET CORP 2.2%
Pacer Advisors, Inc. 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VANGUARD GROUP INC
13F 13D/G
Company · The Vanguard Group
13F 13D/G
10%
from 13D/G
$23,073,356
15,696,161 shares
 — 31 Mar 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
7.1%
from 13D/G
$17,462,019
11,878,924 shares
 — 31 Mar 2025
RENAISSANCE TECHNOLOGIES LLC
13F 13D/G
Company
13F 13D/G
5.4%
from 13D/G
$14,612,523
9,940,492 shares
 — 31 Mar 2025
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
13F 13D/G
2.2%
from 13D/G
$5,142,485
3,498,289 shares
 — 31 Mar 2025
Pacer Advisors, Inc.
13F 13D/G
Company · Pacer US Small Cap Cash Cows ETF
13F 13D/G
1.1%
from 13D/G
$2,629,974
1,789,098 shares
 — 31 Mar 2025
Andrew Dreyfus
3/4/5
Director
3/4/5
0.14%
$212,331
228,313 shares
 — 10 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
151
Shares
146,448,573
Rows available
151
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
200
Q2 2025 holders
151
Holder diff
-49
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .